Trials / Completed
CompletedNCT05255900
Effects of Metyrapone in Patients With Hypercortisolism
Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Istituto Auxologico Italiano · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers, mental health and cortisol circadian rhythm.
Detailed description
This open prospective observational study will include patients with mild hypercortisolism of both adrenal and pituitary origin not candidate for surgery. Patients taking metyrapone since less than a week will be followed up for 24 weeks. During this period of time, patients will be re-evaluated as far as blood pressure control, glycometabolic control, thrombotic risk parameters, lipid profile, bone turnover markers and cortisol circadian rhythm is concerned.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metyrapone Capsules | Exposure to 24 weeks of treatment with metyrapone |
Timeline
- Start date
- 2022-04-28
- Primary completion
- 2025-06-30
- Completion
- 2025-12-31
- First posted
- 2022-02-25
- Last updated
- 2026-03-30
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT05255900. Inclusion in this directory is not an endorsement.